CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American
Provided By GlobeNewswire
Last update: May 16, 2025
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
Read more at globenewswire.comNASDAQ:CAMP (12/11/2025, 10:19:17 AM)
5.69
-0.03 (-0.52%)
Find more stocks in the Stock Screener
